Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
36
CVAC Quote, Financials, Valuation and Earnings
Last price:
$3.00
Seasonality move
:
-28.45%
Day range:
$2.93 - $3.02
52-week range:
$2.22 - $5.28
Dividend yield:
0%
P/E ratio:
5.45x
P/S ratio:
1.13x
P/B ratio:
0.83x
Volume:
176.5K
Avg. volume:
590.7K
1-year change:
-26.35%
Market cap:
$670.8M
Revenue:
$58.2M
EPS (TTM):
$0.55
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CVAC
CureVac NV
|
$150.6M | $1.54 | -66% | -69.73% | $7.38 |
|
AFMD
Affimed NV
|
$1.5M | -$1.06 | -50.03% | -42.4% | $18.90 |
|
BAYRY
Bayer AG
|
$11B | $0.17 | -5.74% | -27.67% | -- |
|
BNTX
BioNTech SE
|
$561.1M | -$1.75 | -24.68% | -74.38% | $137.54 |
|
IFRX
InflaRx NV
|
$84.1K | -$0.27 | 5602.11% | -2.23% | $8.04 |
|
IMTX
Immatics NV
|
$17.4M | -$0.28 | -5.77% | -3.64% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CVAC
CureVac NV
|
$2.99 | $7.38 | $670.8M | 5.45x | $0.00 | 0% | 1.13x |
|
AFMD
Affimed NV
|
$1.24 | $18.90 | $20.3M | -- | $0.00 | 0% | 20.08x |
|
BAYRY
Bayer AG
|
$4.87 | -- | $19.1B | -- | $0.03 | 0.6% | 0.38x |
|
BNTX
BioNTech SE
|
$114.13 | $137.54 | $27.4B | 184.86x | $0.00 | 0% | 8.34x |
|
IFRX
InflaRx NV
|
$2.51 | $8.04 | $147.8M | -- | $0.00 | 0% | 800.79x |
|
IMTX
Immatics NV
|
$7.10 | -- | $863M | -- | $0.00 | 0% | 5.70x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CVAC
CureVac NV
|
-- | 2.309 | -- | 6.10x |
|
AFMD
Affimed NV
|
31.93% | 0.815 | 16.35% | 1.76x |
|
BAYRY
Bayer AG
|
-- | 0.334 | -- | 0.81x |
|
BNTX
BioNTech SE
|
1.26% | 0.543 | 0.96% | 7.10x |
|
IFRX
InflaRx NV
|
-- | 4.286 | -- | 4.34x |
|
IMTX
Immatics NV
|
-- | 1.740 | -- | 3.87x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CVAC
CureVac NV
|
$519.1M | $404.1M | 21.3% | 21.3% | 75.06% | $381.2M |
|
AFMD
Affimed NV
|
-- | -$15.7M | -127.62% | -158.94% | -9594.22% | -$13.2M |
|
BAYRY
Bayer AG
|
$5.4B | -$4.2B | -2.23% | -2.79% | -37.17% | $1.6B |
|
BNTX
BioNTech SE
|
$1.2B | $11.5M | -2.32% | -2.35% | 13.39% | -$770.2M |
|
IFRX
InflaRx NV
|
$216K | -$16.9M | -61.55% | -61.55% | -14084.63% | -$11.2M |
|
IMTX
Immatics NV
|
-- | $565.3K | -16.88% | -16.88% | -4.19% | -$42M |
CureVac NV vs. Competitors
-
Which has Higher Returns CVAC or AFMD?
Affimed NV has a net margin of 68.44% compared to CureVac NV's net margin of -9767.12%. CureVac NV's return on equity of 21.3% beat Affimed NV's return on equity of -158.94%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV95.56% $1.65 $809.4M AFMDAffimed NV-- -$1.03 $28.2M -
What do Analysts Say About CVAC or AFMD?
CureVac NV has a consensus price target of $7.38, signalling upside risk potential of 144.29%. On the other hand Affimed NV has an analysts' consensus of $18.90 which suggests that it could grow by 1421.72%. Given that Affimed NV has higher upside potential than CureVac NV, analysts believe Affimed NV is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV3 4 0 AFMDAffimed NV5 1 0 -
Is CVAC or AFMD More Risky?
CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Affimed NV has a beta of 2.063, suggesting its more volatile than the S&P 500 by 106.315%.
-
Which is a Better Dividend Stock CVAC or AFMD?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Affimed NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. Affimed NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or AFMD?
CureVac NV quarterly revenues are $543.2M, which are larger than Affimed NV quarterly revenues of $170.5K. CureVac NV's net income of $371.8M is higher than Affimed NV's net income of -$16.7M. Notably, CureVac NV's price-to-earnings ratio is 5.45x while Affimed NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.13x versus 20.08x for Affimed NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV1.13x 5.45x $543.2M $371.8M AFMDAffimed NV20.08x -- $170.5K -$16.7M
-
Which has Higher Returns CVAC or BAYRY?
Bayer AG has a net margin of 68.44% compared to CureVac NV's net margin of -41.96%. CureVac NV's return on equity of 21.3% beat Bayer AG's return on equity of -2.79%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV95.56% $1.65 $809.4M BAYRYBayer AG48.94% -$1.17 $34.3B -
What do Analysts Say About CVAC or BAYRY?
CureVac NV has a consensus price target of $7.38, signalling upside risk potential of 144.29%. On the other hand Bayer AG has an analysts' consensus of -- which suggests that it could grow by 55.85%. Given that CureVac NV has higher upside potential than Bayer AG, analysts believe CureVac NV is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV3 4 0 BAYRYBayer AG0 0 0 -
Is CVAC or BAYRY More Risky?
CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bayer AG has a beta of 1.041, suggesting its more volatile than the S&P 500 by 4.07%.
-
Which is a Better Dividend Stock CVAC or BAYRY?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bayer AG offers a yield of 0.6% to investors and pays a quarterly dividend of $0.03 per share. CureVac NV pays -- of its earnings as a dividend. Bayer AG pays out -80.89% of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or BAYRY?
CureVac NV quarterly revenues are $543.2M, which are smaller than Bayer AG quarterly revenues of $11B. CureVac NV's net income of $371.8M is higher than Bayer AG's net income of -$4.6B. Notably, CureVac NV's price-to-earnings ratio is 5.45x while Bayer AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.13x versus 0.38x for Bayer AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV1.13x 5.45x $543.2M $371.8M BAYRYBayer AG0.38x -- $11B -$4.6B
-
Which has Higher Returns CVAC or BNTX?
BioNTech SE has a net margin of 68.44% compared to CureVac NV's net margin of 15.91%. CureVac NV's return on equity of 21.3% beat BioNTech SE's return on equity of -2.35%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV95.56% $1.65 $809.4M BNTXBioNTech SE85.63% $0.89 $21.6B -
What do Analysts Say About CVAC or BNTX?
CureVac NV has a consensus price target of $7.38, signalling upside risk potential of 144.29%. On the other hand BioNTech SE has an analysts' consensus of $137.54 which suggests that it could grow by 20.51%. Given that CureVac NV has higher upside potential than BioNTech SE, analysts believe CureVac NV is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV3 4 0 BNTXBioNTech SE11 5 0 -
Is CVAC or BNTX More Risky?
CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioNTech SE has a beta of 0.217, suggesting its less volatile than the S&P 500 by 78.349%.
-
Which is a Better Dividend Stock CVAC or BNTX?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or BNTX?
CureVac NV quarterly revenues are $543.2M, which are smaller than BioNTech SE quarterly revenues of $1.4B. CureVac NV's net income of $371.8M is higher than BioNTech SE's net income of $217.9M. Notably, CureVac NV's price-to-earnings ratio is 5.45x while BioNTech SE's PE ratio is 184.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.13x versus 8.34x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV1.13x 5.45x $543.2M $371.8M BNTXBioNTech SE8.34x 184.86x $1.4B $217.9M
-
Which has Higher Returns CVAC or IFRX?
InflaRx NV has a net margin of 68.44% compared to CureVac NV's net margin of -14092.9%. CureVac NV's return on equity of 21.3% beat InflaRx NV's return on equity of -61.55%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV95.56% $1.65 $809.4M IFRXInflaRx NV-5376.61% -$0.33 $72.9M -
What do Analysts Say About CVAC or IFRX?
CureVac NV has a consensus price target of $7.38, signalling upside risk potential of 144.29%. On the other hand InflaRx NV has an analysts' consensus of $8.04 which suggests that it could grow by 220.48%. Given that InflaRx NV has higher upside potential than CureVac NV, analysts believe InflaRx NV is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV3 4 0 IFRXInflaRx NV3 1 0 -
Is CVAC or IFRX More Risky?
CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.675, suggesting its more volatile than the S&P 500 by 67.534%.
-
Which is a Better Dividend Stock CVAC or IFRX?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or IFRX?
CureVac NV quarterly revenues are $543.2M, which are larger than InflaRx NV quarterly revenues of $136.2K. CureVac NV's net income of $371.8M is higher than InflaRx NV's net income of -$19.2M. Notably, CureVac NV's price-to-earnings ratio is 5.45x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.13x versus 800.79x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV1.13x 5.45x $543.2M $371.8M IFRXInflaRx NV800.79x -- $136.2K -$19.2M
-
Which has Higher Returns CVAC or IMTX?
Immatics NV has a net margin of 68.44% compared to CureVac NV's net margin of -16.95%. CureVac NV's return on equity of 21.3% beat Immatics NV's return on equity of -16.88%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV95.56% $1.65 $809.4M IMTXImmatics NV-- -$0.12 $427.2M -
What do Analysts Say About CVAC or IMTX?
CureVac NV has a consensus price target of $7.38, signalling upside risk potential of 144.29%. On the other hand Immatics NV has an analysts' consensus of -- which suggests that it could grow by 135.92%. Given that CureVac NV has higher upside potential than Immatics NV, analysts believe CureVac NV is more attractive than Immatics NV.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV3 4 0 IMTXImmatics NV6 0 0 -
Is CVAC or IMTX More Risky?
CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immatics NV has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.688%.
-
Which is a Better Dividend Stock CVAC or IMTX?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or IMTX?
CureVac NV quarterly revenues are $543.2M, which are larger than Immatics NV quarterly revenues of $55.6M. CureVac NV's net income of $371.8M is higher than Immatics NV's net income of -$9.4M. Notably, CureVac NV's price-to-earnings ratio is 5.45x while Immatics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.13x versus 5.70x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV1.13x 5.45x $543.2M $371.8M IMTXImmatics NV5.70x -- $55.6M -$9.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
